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Abstract
Introduction: The smell, subjective phenomenon of great importance, is poorly under-
stood and studied in humans. Physicians with more knowledge about smell disorders 
tend to consider the phenomenon important and to better manage the diagnosis and its 
treatment. 
Aims: First to describe a sample of patients presenting with main complaint of disturbances 
of smell. And second, to show our experience on management and treatment of this disease. 
Design: Retrospective cross-sectional cohort study. 
Materials and methods: Sample description and assessment of treatment response in patients 
with main complaint of hyposmia or anosmia from January 2005 to October 2011. 
Results: From 38 patients presented with main complaint of an olfactory disorder, 68.4% of 
the patients were presented with hyposmia and 31,5% with anosmia, with a mean duration of 
30.8 months. The main etiologic diagnoses were idiopathic (31.5%), rhinitis (28.9%) and CRS 
with polyps (10.5%). Responses to treatment with topical steroids and alpha-lipoic acid were 
variable, as well as in the literature.
Conclusion: Greater importance should be given to disorders of smell in practice of otolaryn-
gologists, since its large differential diagnosis and the fact that could increase morbidity to 
patients, impacting on their quality of life.
© 2014 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier 
Editora Ltda. All rights reserved.
 
Distúrbios da olfação: estudo retrospectivo 
Resumo
Introdução: O olfato, fenômeno subjetivo de grande importância, é pouco compreendido e 
estudado no ser humano. Médicos com maior conhecimento sobre os distúrbios desse sentido 
tendem a considerar a doença mais importante e manejar melhor o diagnóstico e o tratamento.
Objetivo: Descrever a amostra dos pacientes com queixa principal de distúrbios do olfato e 
mostrar a experiência do serviço no manejo e tratamento.
Delineamento: Estudo retrospectivo de coorte histórica com corte transversal.
Materiais e métodos: Descrição da amostra e avaliação de resposta ao tratamento de pacientes 
com queixa principal de hiposmia ou anosmia atendidos no ambulatório de Rinologia no período 
de janeiro de 2005 a outubro de 2011. 
Please cite this article as: Gregorio LL, Caparroz F, Nunes LM, Neves LR, Macoto EK. Olfaction disorders: retrospective study. Braz J Oto-
rhinolaryngol. 2014;80:11-7.
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Introduction
Olfaction disorders have attained great importance in re-
cent years. In humans, the sense of smell is probably the 
least understood, being mostly a subjective phenomenon.1 
Anosmia and hyposmia are terms that refer to the complete 
and partial loss of smell, respectively. The term dysosmia, in 
turn, describes an altered sense of smell, both in response 
to environmental stimuli (an alteration termed parosmia) 
and spontaneous events (termed phantosmia).2
The loss or impairment of olfaction is a relatively com-
mon condition, especially in the elderly. Doty et al. esti-
mated that approximately 75% of individuals older than 80 
years and 50% of those between 65 and 80 years suffer from 
considerable decrease in olfactory function.3 However, the 
prevalence of olfaction disorders in the general population 
was and has been underestimated, as indicated by some re-
cent studies. In a study with a representative sample of the 
population (n = 1,387) performed in Sweden, a prevalence 
of 19% was calculated for olfaction disorders in general.4
Moreover, it is well established that the sense of smell 
strongly contributes to taste perception, so that patients 
with hyposmia or anosmia have great difficulty in perceiving 
the taste of food, thus losing the appetite for and pleasure 
from food.1 The olfactory impulses propagate to the limbic 
system, as well as to the higher cortical areas. Certain ol-
factory stimuli may trigger diverse emotional responses and 
create different cortical associations with other senses; this 
process is connected to the individual’s memory and the 
perception of emotional stimulus quality, i.e., the feeling 
of being pleasant or unpleasant.1
Another factor to consider is that hyposmia may cause a 
significant impact on the quality of life of patients, bringing 
difficulties in activities of daily living, mood disorders, de-
creased appetite, and even work problems.5 
Standardized olfactory tests were created in an attempt 
to objectify a subjective symptom since olfaction disorders 
are sources of several medical complaints and result in 
thousands of annual physician visits.6 In this sense, olfac-
tory dysfunction has been investigated as one of the earli-
est pre-clinical signs in both Alzheimer’s disease (AD) and in 
sporadic Parkinson’s disease (PD).7 
In a recent study performed with questionnaires applied 
to otolaryngologists (n = 231), it was observed that only 7.3% 
of participants reported using olfaction assessment tests in 
daily clinical practice. It was demonstrated that most physi-
cians observed tests being applied and received training on 
testing for olfaction disorders during the residency period. 
In addition, physicians with greater knowledge about these 
disorders tend to consider the disease to be more import-
ant, and therefore achieve better diagnosis and treatment.8 
This study aimed to describe the sample of patients 
with a complaint of olfaction disorders, report this ser-
vice’s experience in the management of these patients, 
and review the literature on olfaction disorders with em-
phasis on olfaction assessment methods, etiological diag-
nosis, and conduct.  
Method
This was a retrospective historical cohort study of patients 
treated at a rhinology outpatient clinic of a tertiary hos-
pital with a chief complaint of olfaction disorder (anos-
mia and hyposmia) during the period of January of 2005 
to October of 2011. The following were evaluated: age, 
gender, duration of complaint, symptoms at diagnosis (na-
sal obstruction, anterior or posterior rhinorrhea, epistaxis, 
headache, among others), comorbidities, as well as findings 
during the otorhinolaryngology examination and findings at 
the complementary imaging assessment. The percentage of 
improvement with different treatments according to each 
diagnostic hypothesis was also evaluated. 
On physical examination, the following were consid-
ered to be positive findings: presence of nasal polyps at 
any grade and location; septal deviation grades II and III; 
inferior turbinate hypertrophy with pale mucosa; and pres-
ence of secretion in the middle meatus. Regarding the com-
puted tomography (CT) findings of the paranasal sinuses, 
the following were considered as positive: obstruction of the 
ostium-meatal complex; partial or complete opacification 
of one or more paranasal sinuses; and presence of concha 
bullosa. No standardized routine olfactory tests were ap-
plied during patient assessment.
Results
The study was submitted to and approved by the Eth-
ics Committee of Plataforma Brasil under CAAE No. 
07390412.9.0000.5505. All outpatients complaining of olfac-
tion disorders treated at the rhinology outpatient clinic of 
a tertiary hospital from January of 2005 to October of 2011 
(n = 38) were included. Patients with minor complaints of 
Resultados: Dos 38 pacientes com distúrbio da olfação, 68,4% dos pacientes apresentaram quei-
xa de hiposmia e 31,5% de anosmia, com duração média de 30,8 meses. Os diagnósticos etioló-
gicos principais foram idiopática (31,5%), rinopatia alérgica (28,9%) e RSC com pólipos (10,5%). 
As respostas ao tratamento com corticosteroide tópico e ácido alfa-lipoico foram variáveis, 
assim como na literatura. 
Conclusão: Maior importância deve ser dada aos distúrbios do olfato na prática do otorrinola-
ringologista, uma vez que o diagnóstico diferencial é amplo e pode trazer grande morbidade ao 
paciente, com impacto na sua qualidade de vida. 
© 2014 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Publicado por Elsevier 
Editora Ltda. Todos os direitos reservados.
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anosmia or hyposmia and those who had incomplete data in 
medical records were excluded. Sample characteristics are 
shown in Table 1.
The initial complaints and their duration are described 
in Table 2. The distribution of diagnoses found in the evalu-
ation of patients is shown in Table 3. Patients’ comorbidities 
are shown in Table 4.
Regarding the physical examination findings, 18 (47.3%) 
of 38 patients had one or more criteria at physical examina-
tion described as positive. Regarding the CT examination, it 
was requested for 20 patients (52.6%), of whom seven were 
positive, and 13 showed no alterations. It is important to 
mention that no other alterations or anatomical variations 
that could influence ostium-meatal complex drainage (e.g., 
paradoxical middle turbinate, Haller cells) were observed in 
any of the cases. 
Of all the patients in the sample who sought the outpa-
tient clinic with complaints of olfaction disorders, 8 (21%) 
had undergone previous treatment at another service.
Of these, only four (50%) had partial improvement. Thir-
ty-four patients (89.4%) received drug treatment in this ser-
vice. The therapeutic options are detailed in Table 5. 
Table 6 shows the type of treatment in the main etio-
logical diagnoses of the patients in this sample, with the 
respective improvement percentages. 
A minimum follow-up of 2 months was attained in 57.8% 
of patients to assess treatment response. Of these, 16 
(72.7%) patients showed partial or full response to treat-
ment.
Discussion
The sense of smell is quite undervalued in humans, despite 
its usefulness not only in monitoring the entry of harmful 
agents in the upper airways, but also in largely determining 
taste and palatability of foods or drinks.7 A normal percep-
tion of smell is important for the safety, nutritional status, 
and quality of life of an individual.9 Hyposmia or anosmia are 
associated with several conditions, such as PD, AD, Down’s 
syndrome, multiple sclerosis, and schizophrenia, among 
others.10 Recently, neuroimaging studies determined that 
Table 1 Sample characteristics.
Demographics
Frequency
n %
Gender
Male 15 39.47%
Female 23 60.53%
Age (years)
Mean 54.26
Standard deviation 13.53
Minimum 22
Maximum 87
Table 2 Distribution of initial complaints and symptom duration.
Complaint
Frequency
n %
Hyposmia  26 68.4
Anosmia  12 31.5
Duration (months)
Mean  30.84
Minimum    3
Maximum 120
Table 3 Distribution of diagnosis.
Diagnoses
Frequency
n %
Idiopathic hyposmia 12 31.5
Allergic rhinopathy 11 28.9
Chronic rhinosinusitis
with polyps  4 10.5
no polyps  3   7.8
Senile hyposmia  2   5.2
Hyposmia post-TBI  1   2.6
Iatrogenic hyposmia  1   2.6
Drug-related hyposmia  1   2.6
Post-infectious hyposmia  1   2.6
Cystic fibrosis  1   2.6
Hyposmia post-CVA  1   2.6
CVA, cerebrovascular accident.
Table 4 Comorbidities.
Comorbidities
Frequency
n %
Systemic arterial 
hypertension 
15 39.4
Diabetes mellitus  6 15.7
Dyslipidemia  4 10.5
Systemic lupus 
erythematosus 
 1   2.6
Asthma  1   2.6
Osteoporosis  1   2.6
Lymphoma  1   2.6
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patients with anosmia show loss of cortical gray matter vol-
ume in certain areas (such as the medial prefrontal cortex), 
thus postulating an association between the development of 
neurodegenerative diseases and patients with anosmia.11,12 
Nevertheless, few otolaryngologists have enough knowledge 
on olfaction disorders.8 A recent study in Turkey indicated 
that 83.5% of otolaryngologists did not observe the imple-
mentation of standardized olfaction assessment tests during 
the residency period.8 The lack of knowledge and training 
of physicians in their daily practice can lead to misdiagnosis 
and mismanagement of olfaction disorders. 
When assessing the patient, the clinical history is the 
most important tool to attain the diagnosis. Important 
questions are: time of loss, associated concomitant factors 
(e.g., history of head trauma or a history of upper respi-
ratory tract infections [URTIs]), characterization of total 
(anosmia) or partial loss (hyposmia), uni/bilaterality, pres-
ence of olfactory sense fluctuation, other associated nasal 
symptoms, characterization of the onset as sudden or in-
sidious, and the presence of concomitant neurological signs 
and symptoms.  
The supplementary examination can indicate underlying 
liver, kidney, or even neurological diseases. The history of 
Table 5 Drug treatment prescribed to patients.
Drug treatment 
Frequency
n %
Topic corticosteroid 13 38.24
Topic corticosteroid + 
α-lipoic acid
 9 26.47
Topic corticosteroid +  
oral corticosteroid 
 4 11.76
Topic corticosteroid +  
anti-histaminic agent
 4 11.76
Topic corticosteroid +  
ATB + nasal lavage 
 2  5.88
Oral corticosteroid  1  2.94
α-lipoic acid  1  2.94
ATB, antibiotic therapy.
Table 6 Type of treatment stratified by diagnosis.
Diagnosis/treatment Improvement No improvement
n % n % n %
Idiopathic hyposmia
Topic corticosteroid + α-lipoic acid 6   54.5% 1   16.6% 4 80%
Topic corticosteroid 3   27.3%
Systemic corticosteroid 1     9.1%
α-lipoic acid 1     9.1%
Allergic rhinopathy
Topic corticosteroid 6   50% 3   50%
Topic corticosteroid + α-lipoic acid 2   16.7% 2 100% 0   0%
Topic corticosteroid + anti-histaminic drug 2   16.7% 2 100% 0   0%
Topic + systemic corticosteroid 1     8.3%
Chronic rhinosinusitis 
Topic corticosteroid + ATB + NL 2   66.7% 2   66.7% 0   0%
Topic corticosteroid 1   33%
Topic corticosteroid + anti-histaminic drug 1 100% 1 100% 0   0%
Topic + systemic corticosteroid 3 100% 1   33.3%
ATB, antibiotic therapy; NL, nasal lavage.
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a sensitive tool in the assessment of olfaction disorders in 
Brazil. In a recent study, the findings of a study that applied 
this questionnaire were consistent with those obtained 
in the literature, showing a better performance in females 
compared to males in identifying odors.9 
Regarding the etiology, over 200 causes of olfactory dis-
orders have been reported. Among these, four main causes 
stand out, excluding age-related hyposmia: traumatic brain 
injury (TBI), URTIs, chronic rhinosinusitis (CRS) with or with-
out nasal polyps, and the idiopathic form. These four caus-
es account for 70% to 85% of all causes of hyposmia.2 These 
causes can be divided into two large groups according to their 
physiopathology: sensorineural or conduction diseases. The 
former includes olfactory nerve or central nervous system in-
jury, damage from upper airway infections, traumatic brain 
injury, neurotoxins, and lastly, CRS without polyps.  
The causes of conduction, in turn, include nasal tumors, 
traumatic septal deviations affecting the cribriform plate, 
and CRS with polyps.13 This classification is often confus-
ing, as some causes can be identified as both conduction 
and sensorineural, such as CRS. For this reason, the authors 
chose not to apply this classification in the present sample.
Some studies have identified traumatic brain injury (TBI) 
as one of the most frequent causes. A review of large se-
ries of patients after TBI demonstrated that 5% to 7% of all 
trauma cases had anosmia, and occipital or frontal trauma 
was the most common type related to olfaction disorder.2 
Although the trauma intensity is usually directly proportion-
al to the degree of olfactory loss, loss of consciousness may 
not necessarily occur; in addition, mild trauma can cause 
anosmia or hyposmia. Young adult males are most commonly 
affected, as they constitute a risk group to cranial trauma. 
Anosmia is found in up to three-quarters of these patients.2 
The post-viral cause is diagnosed when there is loss of 
olfaction after an upper airway infection, without other ap-
parent cause. These patients typically refer to the URTI as 
“the worst I have ever had.” They tend to be older, with a 
predominance of females at a ratio of 2:1, for still unknown 
reasons. In this case, hyposmia is more common and dysos-
mia can be observed in up to two-thirds of patients.2 Some 
studies suggest that post-viral hyposmia or anosmia should 
always be investigated through imaging exams, treating 
these as diagnosis of exclusion cases, as some underlying 
disease may be present, including intracranial tumors.15  
The sinonasal diseases, in turn, are mentioned as causes 
of hyposmia in approximately 15% of cases.2 Of the patients 
with CRS, approximately 65% to 80% have olfactory dysfunc-
tion.16 Nasal obstruction preventing airflow in the olfactory 
fossa is often identified as the etiological factor in these 
cases, in addition to damage to the neuroepithelium due to 
chronic inflammation. 
For instance, the presence of large polyps in the olfactory 
area prevents the molecules that stimulate the receptors 
from binding to them. In patients with CRS, a study demon-
strated that the presence of nasal polyps, septal deviation, 
inferior turbinate hypertrophy, and (to a lesser extent) 
smoking and allergic rhinitis were predictors of olfactory 
dysfunction.17 These patients may not have nasal complaints 
in addition to hyposmia, and the disease may not be evident in 
the nasal endoscopy. This makes diagnosis more difficult; 
thus, otolaryngologists should be aware of causes that are 
amenable to surgical treatment - chronic rhinosinusitis with 
past or current use of medications is also important.2 In the 
present sample, a case of hyposmia of probable drug-relat-
ed etiology was observed in a patient with underlying diag-
nosis of rheumatoid arthritis using methotrexate. 
The physical examination involves complete otorhinolar-
yngological examination, including flexible endoscope, fo-
cusing on narrowing alterations; changes in the epithelium; 
or presence of abnormalities in the olfactory area. The neu-
rological examination should help in cases directed by the 
clinical history.2 The CT scan of the paranasal sinuses can 
help in the diagnosis of chronic rhinosinusitis and disclose 
areas of hypodensity in the olfactory region. Magnetic res-
onance imaging (MRI), in turn, can be useful in cases of na-
sal tumors invading the lamina cribrosa and central nervous 
system, or in cases of olfactory bulb underdevelopment, or 
even when neurodegenerative processes are suspected.13 
Studies have shown that MRI presents good cost-effec-
tiveness in the etiological diagnosis of olfactory disorders, 
as it can disclose information relevant to the diagnosis in 
up to 25% of cases of idiopathic dysosmia.14 In the present 
study, CT was requested for 52.6% of patients. MRI was less 
often requested (for only one patient) due to the high cost 
and difficulty of access to the examination. 
Regarding the olfaction assessment methods, a large 
variety of tests have been developed in recent decades to 
clinically evaluate the presence or absence of hyposmia or 
anosmia. The originally developed clinical measure consist-
ed of presenting odoriferous substances to patients and ask-
ing them to name these substances sequentially. This meth-
od was shown to be inadequate, as even normal patients 
have difficulties in naming certain types of odors, whereas 
certain substances may produce irritation of the nasal mu-
cosa and stimulate the perception of patients with hypos-
mia. Other methods were shown to be inefficient, as they 
are too time-consuming for clinical use, involving complex 
equipment and showing lack of accuracy in the diagnosis 
of hyposmia – such as the measure of the olfactory evoked 
potentials.10 
Therefore, standardized olfaction assessment tests were 
developed by large specialized centers, which were dissem-
inated for use in clinical assessment due to their practical 
applicability.10 The most commonly used test is the Univer-
sity of Pennsylvania Smell Identification Test (UPSIT), which 
tests for the most common odoriferous particles, encapsu-
lated, including 40 items.2 After being presented each odor 
from a list of four items, patients choose the one that best 
describes the odor they perceived. The total number of 
odors identified is the UPSIT score. This score allows for the 
classification of olfactory function as normosmia, hyposmia 
(mild, moderate, and severe) and anosmia.6 This test can 
be self-applied and takes approximately 15 to 20 minutes. 
It has high reliability, as described in the literature. This 
test helps to solve the problem of concomitant stimulation 
of the trigeminal nerve when presenting odors.6 Its limita-
tions refer primarily to patients with cognitive deficits and 
language problems.10
Other problems were also observed in these standard-
ized tests, such as the presence of false negatives. Deems 
et al. demonstrated that up to 29% of patients complaining 
of loss of smell had no alterations on standardized tests.2 Re-
cently, the UPSIT-Br2 questionnaire was created and adapted 
to the Brazilian sociocultural context;9it was shown to be 
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or without polyps - before assuming the idiopathic cause of 
hyposmia.2 In the present sample, 18.4% of the cases were 
diagnosed with CRS with or without nasal polyps. 
In CRS without nasal polyps, studies have demonstrated 
that the presence of eosinophils in the mucosa of the olfac-
tory epithelium and basal membrane thickening are inde-
pendent predictive factors of olfactory dysfunction.18 Some 
studies also demonstrate that improvement after functional 
endoscopic sinus surgery (FESS) in these patients is variable 
and difficult to predict. In spite of conflicting evidence, it is 
suggested that patients with anosmia and CRS with polyps 
have higher chances of recovering olfactory function after 
surgery than patients with hyposmia without nasal polyps.16 
The tumor causes are often relatively easier to diag-
nose. Meningiomas of the olfactory region and suprasellar 
tumors have also been associated with loss of olfaction. Es-
thesioneuroblastoma, despite being rare, is one of the main 
tumor causes of hyposmia.2
Congenital anosmia (such as Kallman’s syndrome), in 
turn, is found in 1% to 2% of cases, but it is rarely symptom-
atic. Other causes of hyposmia or anosmia include aging, 
acquired immunodeficiency syndrome (AIDS), neurodegen-
erative diseases, liver disease, post-operative trauma (skull 
base surgery), toxins, vitamin and trace element deficien-
cies,2 calcification of the olfactory bulb,19 and sarcoidosis,20 
among others. 
Regarding the treatment, there are still controversies in 
the literature. Randomized studies are still necessary when 
comparing responses to treatment between different etio-
logical groups of olfactory disorders. In some studies, it was 
observed that, in idiopathic hyposmia related to sinonasal 
diseases and in post-infectious diseases, topical corticosteroid 
(mometasone) did not improve olfactory function in a statisti-
cally significant manner after one to three months of use in all 
three groups, while oral corticosteroids (prednisolone at initial 
dose of 40 mg, decreasing for 21 days) had a positive effect.21
Other studies, however, showed improved olfactory 
function after the use of topical corticosteroid (mometa-
sone) in post-infectious hyposmia.22 In the present sample, 
topical corticosteroid alone was used in 13 patients (38.4%), 
with varying responses. The percentage of improvement 
was higher in CRS cases with or without polyps and allergic 
rhinitis, and it was lower in cases of idiopathic hyposmia. In 
a recent prospective study of 32 patients, it was observed 
that the use of topical corticosteroids with a nozzle system 
is more effective in promoting olfaction improvement when 
compared to the traditional spray application system.23
α-lipoic acid, in turn, has been studied for its potential 
antioxidant effects and release of neural factors in olfactory 
function improvement. A beneficial effect was demonstrat-
ed in the recovery of olfactory function after upper airway 
infection with a dose of 600 mg/day for a mean period of 
4.5 months.24 However, there are few studies on its use in 
olfactory disorders. In the present study, the responses to 
α-lipoic acid were variable and difficult to analyze, as in 
most cases it was used as combined therapy. 
Other substances have also been tested in the treatment 
of hyposmia. A recent animal study demonstrated that zinc 
gluconate, a substance that has been frequently used in the 
United States in topical preparations for the treatment of 
the common cold, can have a negative effect on olfactory 
function and cause anosmia.25  
Recently, it was discovered that the olfactory cells have 
a remarkable capacity to regenerate and originate new neu-
rons, a fact that has generated a great momentum in the re-
search on olfactory epithelium cell transplantation. Grafts 
of tissue with olfactory cells not only survive their place-
ment in different regions of the brain, but also conserve the 
characteristics of normal epithelium after transplantation. 
In this sense, it was observed that the axons of olfactory 
sensory cells in olfactory epithelium grafts are able to grow 
toward the cerebral cortex. Furthermore, olfactory epithe-
lium tissue transplanted directly into the olfactory bulb di-
rectly has high survival rates, and ultimately expresses the 
protein found in mature olfactory neurons. Nevertheless, 
several technical questions regarding the placement of the 
grafts are being resolved before this line of research in hu-
mans can be considered.26 
Conclusion
Human olfaction disorders have attained great importance 
in recent years , being investigated as early markers of neu-
rodegenerative diseases such as AD and PD. Nevertheless, 
few otolaryngologists are aware of and consider this issue, 
which may lead to errors in diagnosis and management. To 
describe the sample profile of patients presenting with a 
chief complaint of hyposmia or anosmia in this service, that 
greater emphasis should be given to the initial assessment 
of olfactory disorders, with more accurate diagnoses and 
more detailed etiological research methods, as the differ-
ential diagnosis is broad and can result in great morbidity to 
the patient, with an impact on their quality of life. 
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